# Safety and Immunogenicity of Two Doses, Administered Three Weeks Apart, of Two Monovalent H5N1 Influenza Vaccines Containing 2 Doses of H5N1 Influenza Antigen, in Non-elderly Adult and Elderly Subjects

> **NCT00914771** · PHASE2 · COMPLETED · sponsor: **Novartis Vaccines** · enrollment: 722 (actual)

## Conditions studied

- Pandemic H5N1 Influenza

## Interventions

- **BIOLOGICAL:** H5N1 pandemic Influenza vaccine 3.75µg
- **BIOLOGICAL:** H5N1 pandemic Influenza vaccine 7.5µg

## Key facts

- **NCT ID:** NCT00914771
- **Lead sponsor:** Novartis Vaccines
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-09
- **Primary completion:** 2009-12
- **Final completion:** 2009-12
- **Target enrollment:** 722 (ACTUAL)
- **Last updated:** 2015-10-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00914771

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00914771, "Safety and Immunogenicity of Two Doses, Administered Three Weeks Apart, of Two Monovalent H5N1 Influenza Vaccines Containing 2 Doses of H5N1 Influenza Antigen, in Non-elderly Adult and Elderly Subjects". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00914771. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*